CTCF Variants in 39 Individuals with a Variable Neurodevelopmental Disorder Broaden the Mutational and Clinical Spectrum
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Genome Analysis and Knowledge
Dahary et al. BMC Medical Genomics (2019) 12:200 https://doi.org/10.1186/s12920-019-0647-8 SOFTWARE Open Access Genome analysis and knowledge-driven variant interpretation with TGex Dvir Dahary1*, Yaron Golan1, Yaron Mazor1, Ofer Zelig1, Ruth Barshir2, Michal Twik2, Tsippi Iny Stein2, Guy Rosner3,4, Revital Kariv3,4, Fei Chen5, Qiang Zhang5, Yiping Shen5,6,7, Marilyn Safran2, Doron Lancet2* and Simon Fishilevich2* Abstract Background: The clinical genetics revolution ushers in great opportunities, accompanied by significant challenges. The fundamental mission in clinical genetics is to analyze genomes, and to identify the most relevant genetic variations underlying a patient’s phenotypes and symptoms. The adoption of Whole Genome Sequencing requires novel capacities for interpretation of non-coding variants. Results: We present TGex, the Translational Genomics expert, a novel genome variation analysis and interpretation platform, with remarkable exome analysis capacities and a pioneering approach of non-coding variants interpretation. TGex’s main strength is combining state-of-the-art variant filtering with knowledge-driven analysis made possible by VarElect, our highly effective gene-phenotype interpretation tool. VarElect leverages the widely used GeneCards knowledgebase, which integrates information from > 150 automatically-mined data sources. Access to such a comprehensive data compendium also facilitates TGex’s broad variant annotation, supporting evidence exploration, and decision making. TGex has an interactive, user-friendly, and easy adaptive interface, ACMG compliance, and an automated reporting system. Beyond comprehensive whole exome sequence capabilities, TGex encompasses innovative non-coding variants interpretation, towards the goal of maximal exploitation of whole genome sequence analyses in the clinical genetics practice. This is enabled by GeneCards’ recently developed GeneHancer, a novel integrative and fully annotated database of human enhancers and promoters. -
A Conserved Set of Maternal Genes? Insights from a Molluscan Transcriptome
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Nottingham ePrints Liu, M. Maureen and Davey, John W. and Jackson, Daniel J. and Blaxter, Mark L. and Davison, Angus (2014) A conserved set of maternal genes? Insights from a molluscan transcriptome. International Journal of Developmental Biology, 58 . pp. 501-511. ISSN 0214- 6282 Access from the University of Nottingham repository: http://eprints.nottingham.ac.uk/30007/1/ft501%20%283%29.pdf Copyright and reuse: The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions. · Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. · To the extent reasonable and practicable the material made available in Nottingham ePrints has been checked for eligibility before being made available. · Copies of full items can be used for personal research or study, educational, or not- for-profit purposes without prior permission or charge provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. · Quotations or similar reproductions must be sufficiently acknowledged. Please see our full end user licence at: http://eprints.nottingham.ac.uk/end_user_agreement.pdf A note on versions: The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. -
(P -Value<0.05, Fold Change≥1.4), 4 Vs. 0 Gy Irradiation
Table S1: Significant differentially expressed genes (P -Value<0.05, Fold Change≥1.4), 4 vs. 0 Gy irradiation Genbank Fold Change P -Value Gene Symbol Description Accession Q9F8M7_CARHY (Q9F8M7) DTDP-glucose 4,6-dehydratase (Fragment), partial (9%) 6.70 0.017399678 THC2699065 [THC2719287] 5.53 0.003379195 BC013657 BC013657 Homo sapiens cDNA clone IMAGE:4152983, partial cds. [BC013657] 5.10 0.024641735 THC2750781 Ciliary dynein heavy chain 5 (Axonemal beta dynein heavy chain 5) (HL1). 4.07 0.04353262 DNAH5 [Source:Uniprot/SWISSPROT;Acc:Q8TE73] [ENST00000382416] 3.81 0.002855909 NM_145263 SPATA18 Homo sapiens spermatogenesis associated 18 homolog (rat) (SPATA18), mRNA [NM_145263] AA418814 zw01a02.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:767978 3', 3.69 0.03203913 AA418814 AA418814 mRNA sequence [AA418814] AL356953 leucine-rich repeat-containing G protein-coupled receptor 6 {Homo sapiens} (exp=0; 3.63 0.0277936 THC2705989 wgp=1; cg=0), partial (4%) [THC2752981] AA484677 ne64a07.s1 NCI_CGAP_Alv1 Homo sapiens cDNA clone IMAGE:909012, mRNA 3.63 0.027098073 AA484677 AA484677 sequence [AA484677] oe06h09.s1 NCI_CGAP_Ov2 Homo sapiens cDNA clone IMAGE:1385153, mRNA sequence 3.48 0.04468495 AA837799 AA837799 [AA837799] Homo sapiens hypothetical protein LOC340109, mRNA (cDNA clone IMAGE:5578073), partial 3.27 0.031178378 BC039509 LOC643401 cds. [BC039509] Homo sapiens Fas (TNF receptor superfamily, member 6) (FAS), transcript variant 1, mRNA 3.24 0.022156298 NM_000043 FAS [NM_000043] 3.20 0.021043295 A_32_P125056 BF803942 CM2-CI0135-021100-477-g08 CI0135 Homo sapiens cDNA, mRNA sequence 3.04 0.043389246 BF803942 BF803942 [BF803942] 3.03 0.002430239 NM_015920 RPS27L Homo sapiens ribosomal protein S27-like (RPS27L), mRNA [NM_015920] Homo sapiens tumor necrosis factor receptor superfamily, member 10c, decoy without an 2.98 0.021202829 NM_003841 TNFRSF10C intracellular domain (TNFRSF10C), mRNA [NM_003841] 2.97 0.03243901 AB002384 C6orf32 Homo sapiens mRNA for KIAA0386 gene, partial cds. -
The Bio Revolution: Innovations Transforming and Our Societies, Economies, Lives
The Bio Revolution: Innovations transforming economies, societies, and our lives economies, societies, our and transforming Innovations Revolution: Bio The The Bio Revolution Innovations transforming economies, societies, and our lives May 2020 McKinsey Global Institute Since its founding in 1990, the McKinsey Global Institute (MGI) has sought to develop a deeper understanding of the evolving global economy. As the business and economics research arm of McKinsey & Company, MGI aims to help leaders in the commercial, public, and social sectors understand trends and forces shaping the global economy. MGI research combines the disciplines of economics and management, employing the analytical tools of economics with the insights of business leaders. Our “micro-to-macro” methodology examines microeconomic industry trends to better understand the broad macroeconomic forces affecting business strategy and public policy. MGI’s in-depth reports have covered more than 20 countries and 30 industries. Current research focuses on six themes: productivity and growth, natural resources, labor markets, the evolution of global financial markets, the economic impact of technology and innovation, and urbanization. Recent reports have assessed the digital economy, the impact of AI and automation on employment, physical climate risk, income inequal ity, the productivity puzzle, the economic benefits of tackling gender inequality, a new era of global competition, Chinese innovation, and digital and financial globalization. MGI is led by three McKinsey & Company senior partners: co-chairs James Manyika and Sven Smit, and director Jonathan Woetzel. Michael Chui, Susan Lund, Anu Madgavkar, Jan Mischke, Sree Ramaswamy, Jaana Remes, Jeongmin Seong, and Tilman Tacke are MGI partners, and Mekala Krishnan is an MGI senior fellow. -
Supplementary Table 1 Genes Tested in Qrt-PCR in Nfpas
Supplementary Table 1 Genes tested in qRT-PCR in NFPAs Gene Bank accession Gene Description number ABI assay ID a disintegrin-like and metalloprotease with thrombospondin type 1 motif 7 ADAMTS7 NM_014272.3 Hs00276223_m1 Rho guanine nucleotide exchange factor (GEF) 3 ARHGEF3 NM_019555.1 Hs00219609_m1 BCL2-associated X protein BAX NM_004324 House design Bcl-2 binding component 3 BBC3 NM_014417.2 Hs00248075_m1 B-cell CLL/lymphoma 2 BCL2 NM_000633 House design Bone morphogenetic protein 7 BMP7 NM_001719.1 Hs00233476_m1 CCAAT/enhancer binding protein (C/EBP), alpha CEBPA NM_004364.2 Hs00269972_s1 coxsackie virus and adenovirus receptor CXADR NM_001338.3 Hs00154661_m1 Homo sapiens Dicer1, Dcr-1 homolog (Drosophila) (DICER1) DICER1 NM_177438.1 Hs00229023_m1 Homo sapiens dystonin DST NM_015548.2 Hs00156137_m1 fms-related tyrosine kinase 3 FLT3 NM_004119.1 Hs00174690_m1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 GRIN1 NM_000832.4 Hs00609557_m1 high-mobility group box 1 HMGB1 NM_002128.3 Hs01923466_g1 heterogeneous nuclear ribonucleoprotein U HNRPU NM_004501.3 Hs00244919_m1 insulin-like growth factor binding protein 5 IGFBP5 NM_000599.2 Hs00181213_m1 latent transforming growth factor beta binding protein 4 LTBP4 NM_001042544.1 Hs00186025_m1 microtubule-associated protein 1 light chain 3 beta MAP1LC3B NM_022818.3 Hs00797944_s1 matrix metallopeptidase 17 MMP17 NM_016155.4 Hs01108847_m1 myosin VA MYO5A NM_000259.1 Hs00165309_m1 Homo sapiens nuclear factor (erythroid-derived 2)-like 1 NFE2L1 NM_003204.1 Hs00231457_m1 oxoglutarate (alpha-ketoglutarate) -
Gene Expression Responses in a Cellular Model of Parkinson's Disease
Gene Expression Responses in a Cellular Model of Parkinson's Disease Louis Beverly Brill II Manassas, Virginia B.A., Johns Hopkins University, 1995 A Dissertation presented to the Graduate Faculty of the University of Virginia in Candidacy for the Degree of Doctor of Philosophy Department of Cell Biology University of Virginia May, 2004 Table of Contents Chapter 1 . 1 Chapter 2 . 48 Chapter 3 . 87 Chapter 4 . 123 Chapter 5 . 133 References . 137 Appendix A . 163 Appendix B . 209 Appendix C . 216 Appendix D . 223 Appendix E . 232 Appendix F . 234 Appendix G . 283 Appendix H . 318 Appendix I . 324 Abstract This research represents initial steps towards understanding the relation between changes in gene expression, mitochondrial function and cell death in cell-based models of Parkinson’s disease. The main hypothesis is that rapid gene expression changes in cells exposed to parkinsonian neurotoxins occur, are dependent on mitochondrial status, and directly impact intracellular signaling pathways that determine whether a cell lives or dies. Our cellular model is comprised of SH-SY5Y neuroblastoma cells exposed to the parkinsonian neurotoxin methylpyridinium ion. Transcriptomic changes are evaluated with nylon and glass-based cDNA microarray technology. Cardinal symptoms of Parkinson’s disease, characteristic pathological changes, therapeutic modalities, and current theories on the etiology of the disorder are discussed. Our results verify the existence of mitochondrial-nuclear signaling in the context of electron transport chain deficits, as well as suggesting the vital roles played in this process by previously described intracellular signaling pathways. These results will serve to direct future investigations into gene expression changes relevant to the processes of cell death and cell survival in our cellular model of Parkinson’s disease, and may provide important insights into the pathophysiology of the in vivo disease process. -
1 Novel Expression Signatures Identified by Transcriptional Analysis
ARD Online First, published on October 7, 2009 as 10.1136/ard.2009.108043 Ann Rheum Dis: first published as 10.1136/ard.2009.108043 on 7 October 2009. Downloaded from Novel expression signatures identified by transcriptional analysis of separated leukocyte subsets in SLE and vasculitis 1Paul A Lyons, 1Eoin F McKinney, 1Tim F Rayner, 1Alexander Hatton, 1Hayley B Woffendin, 1Maria Koukoulaki, 2Thomas C Freeman, 1David RW Jayne, 1Afzal N Chaudhry, and 1Kenneth GC Smith. 1Cambridge Institute for Medical Research and Department of Medicine, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0XY, UK 2Roslin Institute, University of Edinburgh, Roslin, Midlothian, EH25 9PS, UK Correspondence should be addressed to Dr Paul Lyons or Prof Kenneth Smith, Department of Medicine, Cambridge Institute for Medical Research, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0XY, UK. Telephone: +44 1223 762642, Fax: +44 1223 762640, E-mail: [email protected] or [email protected] Key words: Gene expression, autoimmune disease, SLE, vasculitis Word count: 2,906 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in Annals of the Rheumatic Diseases and any other BMJPGL products to exploit all subsidiary rights, as set out in their licence (http://ard.bmj.com/ifora/licence.pdf). http://ard.bmj.com/ on September 29, 2021 by guest. Protected copyright. 1 Copyright Article author (or their employer) 2009. -
Best Practice Guidelines for Molecular Analysis of Friedreich Ataxia
European Molecular Genetics Quality Network EMQN Supported by the Standards Measurement and Testing programme of the European Union * * Contract no. SMT4-CT98-7515 Best Practice Guidelines for Molecular Analysis of Friedreich Ataxia Ryan F. 1Dept. of Medical Genetics, University of Groningen, The Netherlands. 2Dept. of Clinical Genetics, Free University Hospital Amsterdam, The Netherlands. 3Center for Human Genetics, University of Leuven, Belgium. 4Institute of Human Genetics, University of Bonn, Germany Guidelines prepared by Fergus Ryan ([email protected]) following discussions at the EMQN workshop 30th June 2000 Disclaimer and can expand into a full mutation in further These Guidelines are based, in most cases, on the reports drawn up generations. This is complicated by the presence of by the chairs of the disease-based workshops run by EMQN and the interruptions to the pure GAA repeat on some CMGS. These workshops are generally convened to address specific technical or interpretative problems identified by the QA scheme. In chromosomes which may have a stabilising effect. many cases, the authors have gone to considerable trouble to collate Pathogenic range expansions result in a significant useful data and references to supplement their reports. However, the reduction in the expression of frataxin and the Guidelines are not, and were never intended to be, a complete resultant physiological manifestations. There is an primer or "how-to" guide for molecular genetic diagnosis of these disorders. The information provided on these pages is intended for inverse correlation between the size of the expansion chapter authors, QA committee members and other interested and the age of onset of the symptoms, indicating that persons. -
Transcription Profiles of the Ductus Arteriosus in Brown-Norway Rats
Advance Publication by-J-STAGE Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Transcription Profiles of the Ductus Arteriosus in Brown-Norway Rats With Irregular Elastic Fiber Formation Yi-Ting Hsieh, BSc; Norika Mengchia Liu, BSc; Eriko Ohmori, BSc; Tomohiro Yokota, PhD; Ichige Kajimura, MD; Toru Akaike, MD, PhD; Toshio Ohshima, MD, PhD; Nobuhito Goda, MD, PhD; Susumu Minamisawa, MD, PhD Background: Patent ductus arteriosus (PDA) is one of the most common congenital cardiovascular defects in children. The Brown-Norway (BN) inbred rat presents a higher frequency of PDA. A previous study reported that 2 different quantitative trait loci on chromosomes 8 and 9 were significantly linked to PDA in this strain. Nevertheless, the genetic or molecular mechanisms underlying PDA phenotypes in BN rats have not been fully investigated yet. Methods and Results: It was found that the elastic fibers were abundant in the subendothelial area but scarce in the media even in the closed ductus arteriosus (DA) of full-term BN neonates. DNA microarray analysis identified 52 upregulated genes (fold difference >2.5) and 23 downregulated genes (fold difference <0.4) when compared with those of F344 control neonates. Among these genes, 8 (Tbx20, Scn3b, Stac, Sphkap, Trpm8, Rup2, Slc37a2, and RGD1561216) are located in chromosomes 8 and 9. Interestingly, it was also suggested that the significant decrease in the expression levels of the PGE2-specfic receptor, EP4, plays a critical role in elastogenesis in the DA. Conclusions: BN rats exhibited dysregulation of elastogenesis in the DA. DNA microarray analysis identified the candidate genes including EP4 involved in the DNA phenotype. -
Clinical Genome Analysis Evidence Review
Clinical genome analysis evidence review Update 2020 Authors: Laura Blackburn, Chantal Babb de Villiers, Joanna Janus, Emma Johnson, Mark Kroese Acknowledgements: The authors would like to thank Karina O’Rourke and Sian Morgan, authors of sections 2.1 and 2.3 respectively. The PHG Foundation is grateful for the insight provided by the individuals consulted during the course of this evidence synthesis. Full acknowledgements are listed in Appendix 1. This review was commissioned and funded by the National Specialist and Screening Services Directorate, NHS Services Scotland NB: URLs in this report were correct as of June 2020 Published by PHG Foundation 2 Worts Causeway Cambridge CB1 8RN UK Tel: +44 (0)1223 761 900 Report produced by PHG Foundation on behalf of NHS Scotland. Copyright NHS Scotland, under licence from PHG Foundation. How to reference this report: Clinical genome analysis evidence review: update 2020 PHG Foundation (2020) This report is the result of PHG Foundation’s independent research and analysis and is not linked to a third party in any way. PHG Foundation has provided occasional analytical services to Oxford Nanopore Technologies (ONT) as part of a consultancy agreement. The PHG Foundation is a health policy think-tank and linked exempt charity of the University of Cambridge. We work to achieve better health through the responsible and evidence based application of biomedical science. We are a registered company, no. 5823194 Contents Executive summary 6 Context 6 The UK genomics policy landscape 6 Summary of findings -
Phd Thesis Matthias Scharenberg.Pdf
Identification and Characterization of Two Isoforms of Human Megakaryoblastic Leukemia-1 and Their Specific Regulation in Myofibroblast Differentiation Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Matthias Scharenberg aus Haan (Rheinland), Deutschland Basel, 2013 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Dieses Werk ist unter dem Vertrag „Creative Commons Namensnennung-Keine kommerzielle Nutzung-Keine Bearbeitung 2.5 Schweiz“ lizenziert. Die vollständige Lizenz kann unter creativecommons.org/licences/by-nc-nd/2.5/ch eingesehen werden. Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Ruth Chiquet-Ehrismann und Prof. Dr. Gerhard Christofori. Basel, den 18.06.2013 Prof. Dr. Jörg Schibler (Dekan) Namensnennung-Keine kommerzielle Nutzung-Keine Bearbeitung 2.5 Schweiz Sie dürfen: das Werk vervielfältigen, verbreiten und öffentlich zugänglich machen Zu den folgenden Bedingungen: Namensnennung. Sie müssen den Namen des Autors/Rechteinhabers in der von ihm festgelegten Weise nennen (wodurch aber nicht der Eindruck entstehen darf, Sie oder die Nutzung des Werkes durch Sie würden entlohnt). Keine kommerzielle Nutzung. Dieses Werk darf nicht für kommerzielle Zwecke verwendet werden. Keine Bearbeitung. Dieses Werk darf nicht bearbeitet oder in anderer Weise verändert werden. • Im Falle einer Verbreitung müssen Sie anderen die Lizenzbedingungen, -
2U11/13U624 A2
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date ft i 20 October 2011 (20.10.2011) 2U11/13U624 A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, C12N 5/10 (2006.01) CI2N 5/074 (2010.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, C12N 15/113 (2010.01) C07H 21/00 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (21) International Application Number: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, PCT/US201 1/032679 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (22) International Filing Date: NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, 15 April 201 1 (15.04.201 1) SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/325,003 16 April 2010 (16.04.2010) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, 61/387,220 28 September 2010 (28.09.2010) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant (for all designated States except US): IM¬ LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, MUNE DISEASE INSTITUTE, INC.